X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2282) 2282
Publication (262) 262
Book Review (22) 22
Book Chapter (3) 3
Conference Proceeding (2) 2
Data Set (1) 1
Dissertation (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
progression-free survival (1901) 1901
humans (1729) 1729
index medicus (1681) 1681
oncology (1423) 1423
female (1241) 1241
middle aged (1099) 1099
male (1025) 1025
aged (982) 982
adult (812) 812
cancer (801) 801
chemotherapy (771) 771
prognosis (617) 617
survival (614) 614
disease-free survival (608) 608
treatment outcome (572) 572
care and treatment (485) 485
overall survival (473) 473
retrospective studies (425) 425
aged, 80 and over (419) 419
metastasis (412) 412
antineoplastic combined chemotherapy protocols - therapeutic use (403) 403
analysis (402) 402
patients (347) 347
hematology (329) 329
therapy (318) 318
tumors (308) 308
antineoplastic agents - therapeutic use (306) 306
research (295) 295
clinical trials (290) 290
survival analysis (275) 275
medicine & public health (271) 271
development and progression (268) 268
patient outcomes (258) 258
hematology, oncology and palliative medicine (250) 250
medical prognosis (248) 248
survival rate (244) 244
neoplasm staging (238) 238
kaplan-meier estimate (228) 228
surgery (227) 227
disease progression (217) 217
young adult (210) 210
cancer therapies (196) 196
drug therapy (188) 188
carcinoma (183) 183
bevacizumab (179) 179
time factors (173) 173
follow-up studies (171) 171
breast cancer (169) 169
medical research (165) 165
health aspects (160) 160
proportional hazards models (159) 159
risk factors (157) 157
trial (157) 157
metastases (155) 155
progression-free (154) 154
adolescent (152) 152
neoplasm metastasis (151) 151
ovarian cancer (151) 151
recurrence (150) 150
open-label (149) 149
radiotherapy (145) 145
studies (143) 143
pharmacology & pharmacy (140) 140
rituximab (139) 139
article (138) 138
randomized controlled trials as topic (138) 138
progression‐free survival (137) 137
biomarkers (136) 136
transplantation (132) 132
antineoplastic agents (128) 128
abridged index medicus (127) 127
antineoplastic combined chemotherapy protocols - adverse effects (126) 126
cisplatin (124) 124
lung cancer (123) 123
multivariate analysis (123) 123
prospective studies (123) 123
medicine, experimental (122) 122
efficacy (121) 121
usage (121) 121
phase-iii trial (120) 120
toxicity (120) 120
neoplasms. tumors. oncology. including cancer and carcinogens (119) 119
antimitotic agents (118) 118
phase-iii (118) 118
lymphomas (117) 117
combined modality therapy (116) 116
phase-ii trial (116) 116
diagnosis (115) 115
cancer research (114) 114
expression (114) 114
colorectal cancer (113) 113
progression free survival (112) 112
phase-ii (111) 111
mutation (110) 110
antineoplastic combined chemotherapy protocols - administration & dosage (109) 109
antineoplastic agents - administration & dosage (107) 107
clinical-trials (105) 105
meta-analysis (105) 105
lung neoplasms - drug therapy (104) 104
non-hodgkins-lymphoma (103) 103
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2264) 2264
Spanish (5) 5
Chinese (4) 4
Japanese (4) 4
Korean (4) 4
German (3) 3
Russian (3) 3
Hungarian (2) 2
French (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by Liu, Jia and Liu, Xiuping and Liu, Wenbin and Liu, Yuexin and Liu, Jianfang and Lichtenberg, Tara M and Lichtenberg, Tara and Hoadley, Katherine A and Poisson, Laila M and Lazar, Alexander J and Cherniack, Andrew D and Kovatich, Albert J and Benz, Christopher C and Benz, Christopher and Levine, Douglas A and Lee, Sandra and Lee, Kenneth and Lee, Adrian V and Lee, Darlene and Lee, Jung Il and Omberg, Larsson and Wolf, Denise M and Wolf, Gregory and Shriver, Craig D and Thorsson, Vesteinn and Caesar-Johnson, Samantha J and Demchok, John A and Felau, Ina and Kasapi, Melpomeni and Ferguson, Martin L and Hutter, Carolyn M and Sofia, Heidi J and Tarnuzzer, Roy and Wang, Zhining and Wang, Jing and Wang, Linghua and Wang, Jioajiao and Wang, Timothy and Wang, Min and Yang, Ian and Yang, Hannah and Yang, Liming and Yang, Ju Dong and Zenklusen, Jean C and Zhang, Lizhi and Zhang, Hongxin and Zhang, Jiexin and Zhang, Hongzheng and Zhang, Hailei and Zhang, Wei and Zhang, Jiashan (Julia) and Chudamani, Sudha and Lolla, Laxmi and Naresh, Rashi and Pihl, Todd and Sun, Yichao and Sun, Qiang and Wan, Yunhu and Wu, Ye and Cho, Juok and DeFreitas, Timothy and Frazer, Scott and Gehlenborg, Nils and Getz, Gad and Heiman, David I and Kim, Jaegil and Lawrence, Michael S and Lin, Pei and Meier, Sam and Noble, Michael S and Saksena, Gordon and Voet, Doug and Bernard, Brady and Chambwe, Nyasha and Dhankani, Varsha and Knijnenburg, Theo and Kramer, Roger and Leinonen, Kalle and Miller, Christopher A and Miller, Michael and Miller, Judy and Reynolds, Sheila and Shmulevich, Ilya and Akbani, Rehan and Broom, Bradley M and Hegde, Apurva M and Ju, Zhenlin and Kanchi, Rupa S and Korkut, Anil and Li, Wei and Li, Jun and Liang, Han and Ling, Shiyun and Lu, Yiling and Mills, Gordon B and Ng, Kwok-Shing and Rao, Arvind and Ryan, Michael and Weinstein, John N and Abeshouse, Adam and ... and Canc Genome Atlas Res Network and Cancer Genome Atlas Research Network
Cell, ISSN 0092-8674, 04/2018, Volume 173, Issue 2, pp. 400 - 416.e11
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 7/2018, Volume 82, Issue 1, pp. 55 - 63
Journal Article
International Journal of Gynecologic Cancer, ISSN 1048-891X, 06/2015, Volume 25, Issue 5, pp. 823 - 829
ObjectiveTo investigate the role of CA-125 percent reduction after neoadjuvant chemotherapy in predicting the extent of the interval debulking surgery (IDS)... 
Neoadjuvant chemotherapy | Interval cytoreduction | Outcome | CA-125 | Overall survival | Progression-free survival | Ovarian cancer | DEBULKING SURGERY | GYNECOLOGIC-ONCOLOGY-GROUP | PROGNOSTIC-FACTORS | ADVANCED OVARIAN-CANCER | FREE SURVIVAL | GROSS RESIDUAL DISEASE | PATHOLOGICAL RESPONSE | OBSTETRICS & GYNECOLOGY | PHASE-III TRIAL | ONCOLOGY | SERUM CA-125 | EPITHELIAL OVARIAN | Neoplasm, Residual - pathology | Prognosis | Follow-Up Studies | Adenocarcinoma, Mucinous - pathology | Endometrial Neoplasms - mortality | Adenocarcinoma, Clear Cell - mortality | Humans | Middle Aged | Ovarian Neoplasms - pathology | Ovarian Neoplasms - mortality | Cystadenocarcinoma, Serous - pathology | Adenocarcinoma, Clear Cell - blood | Cytoreduction Surgical Procedures | Neoplasm Grading | Adenocarcinoma, Mucinous - blood | Cystadenocarcinoma, Serous - therapy | Female | Neoadjuvant Therapy | Retrospective Studies | Chemotherapy, Adjuvant | Neoplasm, Residual - mortality | Adenocarcinoma, Mucinous - therapy | Cystadenocarcinoma, Serous - blood | CA-125 Antigen - blood | Ovarian Neoplasms - blood | Survival Rate | Combined Modality Therapy | Neoplasm, Residual - blood | Mullerian Ducts - pathology | Adenocarcinoma, Mucinous - mortality | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adenocarcinoma, Clear Cell - therapy | Cystadenocarcinoma, Serous - mortality | Endometrial Neoplasms - therapy | Ovarian Neoplasms - therapy | Endometrial Neoplasms - pathology | Adenocarcinoma, Clear Cell - pathology | Aged | Neoplasm Staging | Endometrial Neoplasms - blood | Neoplasm, Residual - therapy
Journal Article
Oncology Reports, ISSN 1021-335X, 12/2012, Volume 28, Issue 6, pp. 2271 - 2277
Journal Article
Biometrics, ISSN 0006-341X, 03/2009, Volume 65, Issue 1, pp. 143 - 151
Summary In many clinical trials patients are intermittently assessed for the transition to an intermediate state, such as occurrence of a disease‐related... 
Clinical trials | Missing status of intermediate transition | Interval censoring | Nonparametric maximum likelihood | Progression‐free survival | Illness–death process
Journal Article
Japanese Journal of Radiology, ISSN 1867-1071, 4/2012, Volume 30, Issue 3, pp. 193 - 197
Journal Article